SG11201404106QA - Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors - Google Patents
Benzyl sulfonamide derivatives useful as mogat - 2 inhibitorsInfo
- Publication number
- SG11201404106QA SG11201404106QA SG11201404106QA SG11201404106QA SG11201404106QA SG 11201404106Q A SG11201404106Q A SG 11201404106QA SG 11201404106Q A SG11201404106Q A SG 11201404106QA SG 11201404106Q A SG11201404106Q A SG 11201404106QA SG 11201404106Q A SG11201404106Q A SG 11201404106QA
- Authority
- SG
- Singapore
- Prior art keywords
- mogat
- inhibitors
- derivatives useful
- sulfonamide derivatives
- benzyl sulfonamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261592717P | 2012-01-31 | 2012-01-31 | |
| EP12382432 | 2012-11-06 | ||
| PCT/US2013/022870 WO2013116075A1 (fr) | 2012-01-31 | 2013-01-24 | Dérivés de benzylsulfanilamide utilisés comme inhibiteurs -2 mogat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201404106QA true SG11201404106QA (en) | 2014-08-28 |
Family
ID=47148691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201404106QA SG11201404106QA (en) | 2012-01-31 | 2013-01-24 | Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US8575352B2 (fr) |
| EP (1) | EP2809651B1 (fr) |
| JP (1) | JP2015511232A (fr) |
| KR (1) | KR20140106750A (fr) |
| CN (1) | CN104066719B (fr) |
| AP (1) | AP2014007794A0 (fr) |
| AR (1) | AR089771A1 (fr) |
| AU (1) | AU2013215468A1 (fr) |
| BR (1) | BR112014018636A8 (fr) |
| CA (1) | CA2859995A1 (fr) |
| CL (1) | CL2014001861A1 (fr) |
| CO (1) | CO7010839A2 (fr) |
| CR (1) | CR20140322A (fr) |
| DO (1) | DOP2014000178A (fr) |
| EA (1) | EA201491276A1 (fr) |
| ES (1) | ES2590929T3 (fr) |
| GT (1) | GT201400167A (fr) |
| HK (1) | HK1199025A1 (fr) |
| IL (1) | IL233712A0 (fr) |
| MA (1) | MA35886B1 (fr) |
| MX (1) | MX2014008599A (fr) |
| PE (1) | PE20141679A1 (fr) |
| PH (1) | PH12014501711A1 (fr) |
| SG (1) | SG11201404106QA (fr) |
| TW (1) | TW201343629A (fr) |
| WO (1) | WO2013116075A1 (fr) |
| ZA (1) | ZA201404836B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9073856B2 (en) | 2012-01-23 | 2015-07-07 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors |
| EA024182B1 (ru) | 2012-01-31 | 2016-08-31 | Эли Лилли Энд Компани | Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2 |
| MX2015005739A (es) | 2012-11-06 | 2015-09-16 | Lilly Co Eli | Compuestos novedosos de bencil sulfonamida utiles como inhibidores de mogat-2. |
| BR112017026739A2 (pt) | 2015-06-15 | 2018-08-28 | Nmd Pharma Aps | compostos para uso no tratamento de distúrbios neuromusculares |
| TWI782056B (zh) | 2017-07-14 | 2022-11-01 | 日商鹽野義製藥股份有限公司 | 具有ｍｇａｔ２抑制活性的縮合環衍生物 |
| US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| US10385028B2 (en) | 2017-12-14 | 2019-08-20 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| MX2021008050A (es) | 2019-01-11 | 2021-08-05 | Shionogi & Co | Derivado de dihidropirazolopirazinona que tiene actividad inhibidora de monoacilglicerol aciltransferasa 2 (mgat2). |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1659113A1 (fr) * | 2004-11-08 | 2006-05-24 | Evotec AG | Inhibiteurs de 11 beta hydroxy stéroid dehydrogenase type 1 (11beta-HSD1) |
| EP1655283A1 (fr) * | 2004-11-08 | 2006-05-10 | Evotec OAI AG | Inhibiteurs de 11béta-HSD1 |
| CA2587149C (fr) * | 2004-11-10 | 2010-02-02 | Pfizer Inc. | Composes de n-sulfonylaminobenzyl-2-phenoxy acetamide substitue |
| CN101087771A (zh) * | 2004-11-10 | 2007-12-12 | 辉瑞大药厂 | 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物 |
| CN101511808A (zh) * | 2006-09-08 | 2009-08-19 | 辉瑞产品公司 | 二芳基醚衍生物及其用途 |
| US8232282B2 (en) * | 2006-09-28 | 2012-07-31 | Dainippon Sumitomo Pharma Co., Ltd. | Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same |
| KR20090064478A (ko) * | 2006-11-13 | 2009-06-18 | 화이자 프로덕츠 인크. | 디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도 |
| WO2009086303A2 (fr) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Procédé permettant de modifier la durée de vie d'organismes eucaryotes |
| WO2010095767A1 (fr) * | 2009-02-23 | 2010-08-26 | Banyu Pharmaceutical Co.,Ltd. | Dérivés de pyrimidin-4(3h)-one |
| US9073856B2 (en) | 2012-01-23 | 2015-07-07 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors |
| EA024182B1 (ru) | 2012-01-31 | 2016-08-31 | Эли Лилли Энд Компани | Новые производные морфолинила, подходящие для применения в качестве ингибиторов mogat-2 |
-
2013
- 2013-01-21 AR ARP130100180A patent/AR089771A1/es unknown
- 2013-01-21 TW TW102102260A patent/TW201343629A/zh unknown
- 2013-01-24 BR BR112014018636A patent/BR112014018636A8/pt not_active IP Right Cessation
- 2013-01-24 CA CA2859995A patent/CA2859995A1/fr not_active Abandoned
- 2013-01-24 EP EP13703234.8A patent/EP2809651B1/fr active Active
- 2013-01-24 PE PE2014001197A patent/PE20141679A1/es not_active Application Discontinuation
- 2013-01-24 KR KR1020147021127A patent/KR20140106750A/ko not_active Application Discontinuation
- 2013-01-24 SG SG11201404106QA patent/SG11201404106QA/en unknown
- 2013-01-24 AP AP2014007794A patent/AP2014007794A0/xx unknown
- 2013-01-24 MX MX2014008599A patent/MX2014008599A/es unknown
- 2013-01-24 AU AU2013215468A patent/AU2013215468A1/en not_active Abandoned
- 2013-01-24 JP JP2014555589A patent/JP2015511232A/ja not_active Ceased
- 2013-01-24 US US13/748,627 patent/US8575352B2/en not_active Expired - Fee Related
- 2013-01-24 CN CN201380007085.XA patent/CN104066719B/zh active Active
- 2013-01-24 ES ES13703234.8T patent/ES2590929T3/es active Active
- 2013-01-24 EA EA201491276A patent/EA201491276A1/ru unknown
- 2013-01-24 WO PCT/US2013/022870 patent/WO2013116075A1/fr active Application Filing
-
2014
- 2014-06-30 ZA ZA2014/04836A patent/ZA201404836B/en unknown
- 2014-07-04 CR CR20140322A patent/CR20140322A/es unknown
- 2014-07-15 CL CL2014001861A patent/CL2014001861A1/es unknown
- 2014-07-17 IL IL233712A patent/IL233712A0/en unknown
- 2014-07-24 CO CO14161422A patent/CO7010839A2/es unknown
- 2014-07-24 MA MA37244A patent/MA35886B1/fr unknown
- 2014-07-29 GT GT201400167A patent/GT201400167A/es unknown
- 2014-07-30 DO DO2014000178A patent/DOP2014000178A/es unknown
- 2014-07-30 PH PH12014501711A patent/PH12014501711A1/en unknown
- 2014-12-11 HK HK14112466.4A patent/HK1199025A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GT201400167A (es) | 2015-05-28 |
| DOP2014000178A (es) | 2014-08-31 |
| AP2014007794A0 (en) | 2014-07-31 |
| ES2590929T3 (es) | 2016-11-24 |
| PH12014501711A1 (en) | 2014-10-13 |
| MX2014008599A (es) | 2014-08-22 |
| JP2015511232A (ja) | 2015-04-16 |
| HK1199025A1 (en) | 2015-06-19 |
| KR20140106750A (ko) | 2014-09-03 |
| ZA201404836B (en) | 2017-08-30 |
| AR089771A1 (es) | 2014-09-17 |
| TW201343629A (zh) | 2013-11-01 |
| US20130197039A1 (en) | 2013-08-01 |
| EP2809651A1 (fr) | 2014-12-10 |
| EA201491276A1 (ru) | 2014-10-30 |
| US8575352B2 (en) | 2013-11-05 |
| CA2859995A1 (fr) | 2013-08-08 |
| MA35886B1 (fr) | 2014-12-01 |
| CO7010839A2 (es) | 2014-07-31 |
| CL2014001861A1 (es) | 2014-11-07 |
| AU2013215468A1 (en) | 2014-07-10 |
| IL233712A0 (en) | 2014-09-30 |
| BR112014018636A2 (fr) | 2017-06-20 |
| WO2013116075A1 (fr) | 2013-08-08 |
| CN104066719A (zh) | 2014-09-24 |
| PE20141679A1 (es) | 2014-11-08 |
| BR112014018636A8 (pt) | 2017-07-11 |
| CR20140322A (es) | 2014-08-25 |
| CN104066719B (zh) | 2016-08-24 |
| EP2809651B1 (fr) | 2016-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2200040I1 (hu) | Benzimidazol-prolin származékok | |
| HK1210775A1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| ZA201305826B (en) | Substituted amminobutyric derivatives as neprilysin inhibitors | |
| HK1205740A1 (en) | Pyrrolotriazinone derivatives | |
| HK1199025A1 (en) | Benzyl sulfonamide derivatives useful as mogat - 2 inhibitors mogat-2 | |
| HK1205508A1 (en) | New bicyclicpyridine derivatives | |
| EP2870140B8 (fr) | Derives de tetrahydroquinazolinone comme inhibiteurs de parp | |
| AP2015008347A0 (en) | Oxazolidin-2-one-pyrimidine derivatives | |
| HK1209422A1 (en) | Fbxo3 inhibitors fbxo3 | |
| PT2838883T (pt) | Novos derivados de fenil-tetra-hidroisoquinolina | |
| HK1199024A1 (zh) | 可作為 抑制物使用之新型嗎啉基衍生物 | |
| ZA201502878B (en) | Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors |